Biljana Horn
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (2)
In the setting of a learning collaborative, we conducted an international multicenter phase 2 clinical trial testing the hypothesis that nonmyeloablative–related haploidentical bone marrow transplant (BMT) with thiotepa and posttransplant cyclophosphamide (PTCy) will result in 2-year event-free survival (no graft failure or death) of at least 80%. A total of 70 participants were evaluable based on the conditioning protocol. Graft failure occurred in 8 of 70 (11.4%) and only in participants aged <18 years; all had autologous reconstitution. After a median follow-up of 2.4 years, the 2-year Kaplan-Meier–based probability of event-free survival was 82.6%. The 2-year overall survival was 94.1%, with no difference between children and adult participants. After excluding participants with graft failure (n = 8), participants with engraftment had median whole blood donor chimerism values at days +180 and +365 after transplant of 100% (n = 58), respectively, and 96.6% (57/59) were off immunosuppression 1 year after transplant. The 1-year grade 3 to 4 acute graft-versus-host disease (GVHD) rate was 10%, and the 2-year moderate–severe chronic GVHD rate was 10%. Five participants (7.1%) died from infectious complications. We demonstrate that nonmyeloablative haploidentical BMT with thiotepa and PTCy is a readily available curative therapy for most adults, even those with organ damage, compared to the more expensive myeloablative gene therapy and gene editing. Additional strategies are required for children to decrease graft failure rates. The trial was registered at www.clinicaltrials.gov as #NCT01850108.
Year:
2024
Background Hematopoietic stem cell transplant (HSCT) is the only curative treatment for several pediatric non‐malignant disorders. A widely used conditioning backbone is busulfan, fludarabine, and rabbit anti‐thymocyte globulin (rATG). Thiotepa has improved engraftment when added to this regimen, however the minimum effective dose (MED) of thiotepa to achieve engraftment while minimizing toxicities has not been well established. Objectives The primary objective of this prospective feasibility study was to determine the MED of thiotepa (5mg/kg) in combination with reduced‐dose busulfan, fludarabine or cyclophosphamide, and rATG required to achieve engraftment in >90% of HSCT recipients for non‐malignant disorders with acceptable toxicity. Results Six patients who received fully matched HSCT were enrolled. Patient diagnoses included Wiskott‐Aldrich syndrome (n = 1), CD40L deficiency (n = 1), sickle cell disease (n = 2), autoinflammatory syndrome (n = 1), and paroxysmal nocturnal hemoglobinuria (n = 1). All six patients achieved engraftment prior to Day +42 and five patients had stable full donor engraftment. Two of the six patients (33%) developed acute GVHD and/or chronic GHVD, both of whom had sickle cell disease. At a median follow‐up of 2.25 years post‐transplant, all patients were alive without evidence of disease recurrence. None of the patients experienced grade 4 or 5 toxicities. Three out of six patients (50%) developed grade 3 adverse events. Neurocognitive functioning of children under 10 years of age was not adversely affected by this regimen. Conclusion This approach shows acceptable toxicity and reliable engraftment in children with non‐malignant disorders receiving related or unrelated HLA‐matched transplants.
Year:
2023
Collaborators (5)
James Connelly
Vanderbilt University Medical Center
Michael R. DeBaun
J.C. Peterson Endowed Chair in Pediatric Pulmonology
Vanderbilt University Medical Center
Erfan Nur
-
Adetola A. Kassim
-
Mahmoud Aljurf
-
Make your next move.
Prepare your application
Review drafts before you send them.